Growth opportunities in health care are all about innovation, and few new, growing markets are heating up as much as renal denervation in medical tech. Renal denervation, a treatment for hypertension, could be a sleeper market to watch: the Millennium Research Group estimates that this medical device market could see revenue of up to $2.9 billion annually by 2021, hardly chump change for top leaders in the device industry.

Yet no growth market is immune to setbacks. Medtronic (NYSE:MDT), one of the early leaders in developing renal denervation solutions with its Symplicity device, stumbled recently in clinical trials over its device's efficacy. U.S. regulatory approval for the Symplicity now looks far off in the future as the company rebounds from this device, and while Medtronic vows to keep the device on schedule, it's no doubt left investors disappointed.

But is Medtronic's setback a stumbling block for the renal denervation push in med tech, or is it just a window of opportunity for other hard-charging rivals in this space, such as St. Jude Medical (NYSE:STJ)? In the video below, Motley Fool contributor Dan Carroll takes you through all you need to know about the renal denervation market's potential -- and which companies and stocks are the early leaders to reap big rewards down the road.

Can these two innovative names revolutionize your portfolio's potential?
Innovation's the name of the game in health care. The best way to play the health care space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Covidien. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Comments